The Life Sciences team advised Kymera Therapeutics on the completion of its $65 million Series B financing to support the advancement of its lead asset into clinical development, and to progress its therapeutic pipeline in oncology and immunology. The financing was co-led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures with participation by MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, and Aju IB Investment, in addition to Kymera’s Series A investors.
Kymera Therapeutics, represented by Goodwin since its inception, is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.
The Goodwin team was led by partner Bill Collins and included partners Daniel Karelitz, James Mattus and Gregg Katz; counsel Jacob Osborn; and associates Gaby Morales-Rivera, Katie Maxwell, Katie Hand, Alex Plaum, and Erini Svokos.
For additional details on the financing, please read the press release.